SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Eris Lifesciences - Quaterly Results

25 Oct 2024 Evaluate
The September 2024 quarter revenue stood at Rs. 4365.60 millions, up 6.55% as compared to Rs. 4097.10 millions during the corresponding quarter last year.Net profit was down at Rs. 281.00  millions against Rs. 1178.10 millions recorded in the corresponding quarter a year ago.The net profit spiraled down by -76.15%.Operating profit for the quarter ended September 2024 decreased to 1484.40 millions as compared to 1514.70 millions of corresponding quarter ended September 2023.


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202409 202309 % Var 202409 202309 % Var 202403 202303 % Var
Sales 4365.60 4097.10 6.55 8932.50 8210.00 8.80 14867.06 13307.25 11.72
Other Income 58.10 69.80 -16.76 109.70 110.10 -0.36 348.28 172.64 101.74
PBIDT 1484.40 1514.70 -2.00 2769.80 3110.10 -10.94 4886.42 5223.78 -6.46
Interest 562.60 65.50 758.93 1124.30 133.90 739.66 574.20 208.10 175.93
PBDT 921.80 1449.20 -36.39 1645.50 2976.20 -44.71 4312.22 5015.68 -14.03
Depreciation 461.60 250.00 84.64 917.10 451.60 103.08 1023.89 646.57 58.36
PBT 460.20 1199.20 -61.62 728.40 2524.60 -71.15 3288.33 4369.11 -24.74
TAX 179.20 21.10 749.29 277.00 238.90 15.95 291.21 389.03 -25.14
Deferred Tax 91.40 -197.30 -146.33 142.30 -196.90 -172.27 -285.23 -375.93 -24.13
PAT 281.00 1178.10 -76.15 451.40 2285.70 -80.25 2997.12 3980.08 -24.70
Equity 136.10 136.00 0.07 136.10 136.00 0.07 136.03 135.99 0.03
PBIDTM(%) 34.00 36.97 -8.03 31.01 37.88 -18.15 32.87 39.26 -16.27

Eris Lifesciences Share Price

1446.50 -18.90 (-1.29%)
17-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1675.20
Dr. Reddys Lab 1235.40
Cipla 1238.30
Zydus Lifesciences 942.55
Lupin 2324.25
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×